| DEALFLOWUPDATE Issue #50. Friday, February 14 |
| Hello Everyone, For this edition of the Zoic newsletter, we continue to see deals in our key focus areas including brain and neural stimulation, infectious diseases, consumer and medical diagnostics. -Neal If this is your first issue, please subscribe and consider sharing with others. Additionally, we welcome news from our readers, if you’re up to something interesting, let us know. Email chad@zoiccapital.com |
Deal Flow Our most recent deal flow report on brain and neural stimulation, infectious diseases as well as consumer and medical diagnostics. We continue to see innovations in using noninvasive stimulation of the brain to improve medical conditions with Alzheimer’s. This is particularly attractive as there is no current treatment for Alzheimer’s, even if there was a way to diagnose it early, which also does not exist. A treatment that is also a device is also appealing, given the recent multiple failures of amyloid-targeting for Alzheimer’s drugs. Read More We still track innovations and opportunities in infectious diseases and vaccines, even though it is traditionally thought of as a field unable to create profit returns. This can be challenged though, especially as the common flu continues to be difficult to manage. The current flu vaccine is inadequate and even decreasing in efficacy each year. A new approach that is more effective and perhaps easier to manufacture could be both beneficial to health and a great investment. Read More In the field of consumer diagnostics, we often cover bio-fluid detection. Another interesting field though is using the eye; a new contact lens could be used to diagnose diabetes as well as diabetic related reinopathy. The eye can also be an interesting view into the brain, as proteins located there and within blood can show up representatively in the retina. Read More Also in the field of consumer diagnostics, 23andme has seen increased use in determining a variety of genetic information, from general wellness to ancestry. However, the company has recently cut back some of its consumer efforts. Some of these cutbacks are probably due to streamlining and reducing inefficiency, but the reductions could also be due to the nature of its testing. Some of the tests offered have been criticized for not offering precise enough information or recommendations, as well as privacy concerns. We feel a consumer genetic test still has major potential, but needs to provide specific, precise diagnosis and recommendations while still complying with needed regulatory requirements. Read More In the field of hospital and critical care diagnostics, sepsis is still a major concern. Catching the major inflammatory response to an infection early is key to patient recovery, and still needs improvement. Tests that are specific to biomarkers still need improvement, in accuracy as well as speed. Using a sensor that can directly and quickly determine the signs early can be a major improvement, as seen in a recent study. Read More What We’re Reading Cowboy Investing The State of Family Investment Offices in 2019 Stanford Social Innovation Review Using Measurement to Manage Impact Exponential View Six Ways Coronavirus Will Change Our World New York Times Michael Bloomberg’s Campaign Suddenly Drops Memes Everywhere Connect With Zoic Capital |
| The Biweekly Dealflow Update, curated by the team at Zoic Capital. |
Brain and Neural Stimulation, Infectious Diseases, Consumer and Medical Diagnostics
Join Zoic's Newsletter
Our team of industry experts and professionals provide industry news, guidance and perspective within the life sciences and medtech investment sectors. To see the type of deals and company innovation we pay attention to, consider receiving our biweekly deal flow newsletter.